Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12a9e9ce63eb0bbf3658453fb50a6d9b |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-661 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate |
2013-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d72a1941b4060dbf28d84c88206a6ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1815f4cc041eaa4b9f0d397d38fb060b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3de79084abaceee7ae83dcd49ec4866e |
publicationDate |
2013-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2013171287-A1 |
titleOfInvention |
Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide) |
abstract |
The present invention relates to immunotherapies that are based on depletion of CD37- positive cells such as B-cells. The present invention provides methods for reduction of CD37-positive cells such as B-cells in an individual / patient using a combination of CD37 antibody /antibodies and ICE. The combination of CD37 antibodies and ICEis shown to have improved anti-tumor efficacy compared to single agent treatment. The application further provides materials and methods for treatment of diseases involving aberrant B-cell activity. |
priorityDate |
2012-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |